RT Journal Article SR Electronic T1 Role of SUVmax and GLUT-1 Expression in Determining Tumor Aggressiveness in Patients With Clinical Stage I Endometrioid Endometrial Cancer JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 843 OP 849 DO 10.1097/IGC.0000000000000301 VO 25 IS 5 A1 Dong Wook Lee A1 Gun Oh Chong A1 Yoon Hee Lee A1 Dae Gy Hong A1 Young Lae Cho A1 Shin Young Jeong A1 Ji Young Park A1 Yoon Soon Lee YR 2015 UL http://ijgc.bmj.com/content/25/5/843.abstract AB Objective The aim of this study was to determine the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in estimating tumor aggressiveness in patients with clinical stage I endometrial cancer and the correlation between aggressiveness and expression of glucose transporter 1 (GLUT-1).Methods 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed on 43 patients with clinical stage I endometrioid endometrial cancer. 18F-fluorodeoxyglucose uptake was quantified by calculating the maximum standardized uptake value (SUVmax) and GLUT-1 expression status based on immunohistochemistry.Results The mean (SD) SUVmax of the primary tumor was 8.55 (5.04). The mean SUVmax and GLUT-1 expression in stage IB and stage IC were significantly higher than that in stage IA (P = 0.001; P = 0.003). The mean (SD) SUVmax was 6.81 (4.55) in grade 1, 10.92 (4.61) in grade 2, and 15.35 (1.34) in grade 3 (grade 1 vs grade 2 and 3; P = 0.005). The mean (SD) GLUT-1 expression was 1.17 (0.94) in grade 1, 2.00 (0.94) in grade 2, and 3.00 (0.00) in grade 3 (grade 1 vs grade 2 and 3; P = 0.017).Conclusions Tumor aggressiveness, such as myometrial invasion or tumor grade, had a positive correlation with the SUVmax and GLUT-1 expression in patients with clinical stage I endometrioid endometrial cancer.